ImmunityBio, NantKwest Ink COVID-19 Joint Development, Manufacturing and Marketing Agreement.
(C)2020 M2 COMMUNICATIONS
- US-based clinical-stage, natural killer cell-based therapeutics company NantKwest, Inc. (NASDAQ: NK) and US-based immunotherapy company ImmunityBio have signed a binding term sheet to jointly develop, manufacture, and market therapeutics and vaccines for COVID-19, the companies said.
ImmunityBio has been selected to participate in Operation Warp Speed, a new national programme aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021.
Efforts will focus on the development, testing, and large-scale manufacturing of ImmunityBio's COVID-19 human adenovirus vaccine candidate.
This is the first vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA, offering the potential for patients to develop long-lasting immunity to the virus.
This novel, E1, E2b, E3 deleted, human adenovirus vector has demonstrated safety in over 125 patients in 13 Phase 1 and 2 trials to date.
Clinical studies performed by the National Cancer Institute have demonstrated that this novel Ad5 may induce antigen-specific T-cell immunity in patients, even in the presence of pre-existing adenoviral immunity.
The companies also said that the US Food and Drug Administration has authorised the use of ImmunityBio's IL-15 (generic name nogapendekin alfa inbakicept) to treat patients prior to the onset of severe disease by potentially activating natural killer cells to mitigate viral replication.
On May 18, NantKwest announced FDA authorization to study the use of mesenchymal stem cell treatments to modulate the immune system's excessive response to COVID-19 infection, thereby potentially reducing the debilitating and sometimes fatal effects of the disease.
To support these coordinated efforts from vaccine to therapeutics, the two companies have signed a binding term sheet to jointly develop, manufacture, and market therapeutics and vaccines for COVID-19.
The binding agreement outlines how development costs will be shared, how profits will be apportioned for any successfully marketed products, and the structure of shared governance of the joint work.
Covid-19 Vaccine: Immunologically "Stealth" Ad5 platform uses E1, E2B, E3 deleted human adenovirus to deliver unique N+S COVID construct with potential for DNA transcription for months leading to long term cell-mediated immunity.
ImmunityBio's COVID-19 vaccine candidate is a novel, engineered Ad5 vaccine (as compared to the one based on the chimpanzee adenovirus currently in COVID-19 vaccine trials in Europe, or the first-generation human adenovirus in trials in China), and the first COVID-19 vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA, which offers the potential for patients to develop long-lasting immunity to the virus.
This human adenovirus platform represents an improvement over first-generation adeno-associated virus vectors, which produce large amounts of adenoviral fiber, which leads to high levels of adenoviral-neutralising antibodies that, in turn, diminish the ability for the vaccine to be produced in the patient and thus limit ongoing immune response.
In addition, the absence of the production of these adenoviral neutralizing antibodies enables this second-generation adenovirus to be administered as a prime and boost (homologous vaccination).
The vaccine is based on a human adeno virus platform, engineered to prevent the generation of adenoviral proteins with the objective that they remain "stealth" after being injected.
This potentially allows long-term production of the vaccine construct in the body, even in the presence of pre-existing neutralizing antibodies. With this unique property of being "immunologically silent" in the human body, the vaccine may produce the vaccine blueprint signal for months, thus maximising the opportunity to establish long term immunity and potential T-cell memory.
This Ad5 platform has already demonstrated safety in elderly and immuno- suppressed patients in the oncology setting.
Large- scale manufacturing facilities at NantKwest have been activated, with an expectation of delivering an Ad5 vaccine in high volumes later this year.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||May 28, 2020|
|Previous Article:||Pacific Neuropsychiatric Specialists to Offer Discounted COVID-19 Antibody Testing.|
|Next Article:||BioDot Accelerates Manufacturing to Meet Global COVID-19 Testing Demand.|